Science
Our research sits where sequence information becomes molecular shape, and where molecular shape becomes behaviour. This page describes that work conceptually.
A nucleic acid can be written down as a string of letters. That description is accurate and almost entirely insufficient. The same string folds, pairs with itself and with its neighbours, and takes on shapes that persist or change depending on its surroundings. Behaviour follows from that arrangement at least as much as from the letters themselves.
Our programme is organized around the space between those two descriptions: what can be read from sequence alone, what only emerges once organization is taken into account, and where the boundary between them sits. That question is what we mean by working at the RNA layer, and it is why our other areas of research sit close to it rather than apart from it.
Research areas
Each area is labelled with its standing in the programme, so the hierarchy is stated rather than implied.
01
Primary focus
We study how nucleic-acid sequence and higher-order organization influence molecular behaviour, and we design and evaluate oligonucleotide architectures against that understanding.
Sequence is only the first layer of information. Architecture, molecular specificity and characterization each constrain one another, so an oligonucleotide is treated as a system rather than as a single molecule.
02
Research area
We study central nervous system, neurological and genetically driven disease biology as areas of research.
These are research areas, not clinical programmes. We describe no candidate, no molecular target and no therapeutic outcome, and nothing here is a claim about treating any condition.
03
Supporting research
We investigate beneficial microbial systems and their molecular outputs as research platforms.
This is preclinical scientific research into microbial systems and the molecules they produce — characterization and biological investigation, not a consumer or wellness product.
Sequence sets the possibilities; conditions decide which of them are realized. A given molecule may hold more than one accessible arrangement, and the balance between them can shift with its environment. We are interested in how stable those arrangements are, how readily one gives way to another, and what that means for how a molecule behaves over time.
Above the level of a single molecule, ordering continues. Molecules associate with one another and with their surroundings, and those larger assemblies have properties that are not obvious from any single component.
We approach an oligonucleotide as a system rather than as an isolated molecule. Architecture, molecular specificity and characterization each place constraints on the others, and a design that looks reasonable against one of them can fail against the rest. Specificity is the discipline of the field: understanding not only what a designed molecule is intended to engage with, but how confidently that intention can be demonstrated.
On mechanisms. Oligonucleotide research covers several distinct molecular approaches. They are not interchangeable and they do not work the same way. We do not state which approach any of our work uses, and nothing on this site should be read as identifying one.
Scope of this page. This is a conceptual account of our research interests. It is not a description of specific candidates, targets, molecular designs, biological material or study designs, and it should not be read as one.
Central nervous system, neurological and genetically driven disease biology is one of the areas we study. Conditions with a genetic basis are, at some level, questions about sequence and about what the molecular machinery does with it — which is the level at which we work.
This is early-stage research. We are not describing a clinical programme, a candidate, a molecular target, a formulation or a route into any tissue. Nothing here is a claim about treating, preventing or modifying the course of any condition.
Abstract network figure — not an anatomical or pathway diagram.
Microbial communities are among the most productive molecular systems available to study. They generate a wide range of molecular outputs, respond to their environment, and maintain organization across scales far larger than a single cell.
We investigate beneficial microbial systems and their molecular outputs as research platforms — as a way of asking our central questions about sequence, structure and organization in a living context. This is preclinical scientific research, not a consumer, wellness or supplement product, and we publish no strain identity or formulation.
Stage. All work described on this site is at a research or preclinical stage. We make no therapeutic, comparative or outcome claims, and nothing here describes an approved product.
No pipeline is published. We do not publish programme names, modalities, targets, indications or development stages. When there is approved public data to show, it will appear here and nowhere earlier.
Research questions only become useful when there is a way to answer them carefully. Our capabilities page describes the kinds of work we are set up to do — computational analysis, molecular characterization, cell-based research, research-stage evaluation, and the documentation that holds them together.
See our capabilitiesContact
If you are a researcher, prospective collaborator or student with a question about our areas of work, we are glad to hear from you.